Twenty-five years of lithium augmentation;Fünfundzwanzig jahre lithiumaugmentation

Nervenarzt

Volumn 78, Issue 11, 2007, Pages 1237-1247

  Bschor, T ^a   Lewitzka, U ^b   Pfennig, A ^b,c   Bauer, M ^b  

^a Judisches Krankenhaus Berlin   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Dex corticotropin releasing hormone test; Lithium; Lithium augmentation; Serotonin; Therapy resistant depression

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; SEROTONIN RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL PRACTICE; DEPRESSION; DRUG INDICATION; HUMAN; LITHIUM BLOOD LEVEL; MAINTENANCE THERAPY; NONHUMAN; PRACTICE GUIDELINE; REVIEW;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; HUMANS; LITHIUM CARBONATE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 36048984116     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2273-5     Document Type: Review

References (78)

1. Adli M, Bauer M, Rush AJ (2006) Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry 59: 1029-1038
2. Adli M, Berghöfer A, Linden M et al. (2002) Effectiveness and feasibility of a standardized stepwise drug treatment algorithm for inpatients with depressive disorders - results of a two-year observational study. J Clin Psychiatry 63: 782-790
3. Adli M, Bschor T, Canata B et al. (1998) Lithium in the treatment of acute depression. Fortschr Neurol Psychiatr 66: 435-441
4. Adli M, Rush AJ, Möller HJ, Bauer M (2003) Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry [Suppl 3] 36: 222-229
5. Adli M, Wiethoff K, Baghai T, Bauer M (2005) Algorithmusgestützte Behandlung stationärer Patienten mit depressiven Erkrankungen: das Berliner Algorithmusprojekt. In: Bauer M, Berghöfer A, Adli M (Hrsg) Therapieresistente Depressionen. Springer Medizin, Heidelberg, S 477-487
6. Adli M, Wiethoff K, Baghai TC et al. (2005) Evaluating algorithm-guided treatment for depression: The German Algorithm Project (GAP) [Abstract]. Pharmacopsychiatry 38: A002
7. Álvarez E, Pérez-Solá V, Pérez-Blanco J et al. (1997) Predicting outcome of lithium added to antidepressants in resistant depression. J Affect Disord 42: 179-186
8. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) (Hrsg) (2006) Empfehlungen zur Therapie der Depression. 2. Aufl. Arzneiverordnung in der Praxis, 33, Sonderheft 1
9. Bauer M, Bschor T, Kunz D et al. (2000) Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 157: 1429-1435
10. Bauer M, Crossley NA, Gerber S, Bschor T (2006) The acute antidepressive effects of lithium: from monotherapy to augmentation therapy in major depression. In: Bauer M, Grof P, Müller-Oerlinghausen B (eds) Lithium in neuropsychiatry. The comprehensive guide. Informa healthcare, London, pp 109-127
11. Bauer M, Döpfmer S (1999) Lithium augmentation in treatment-resistant depression - A meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19: 427-434
12. Bauer M, Trendelenburg M, Bschor T (2005) Augmentationsbehandlung mit Lithium. In: Bauer M, Berghöfer A, Adli M (Hrsg) Akute und therapieresistente Depressionen. Springer Medizin Verlag, Heidelberg, S 229-242
13. Bauer M, Whybrow PC, Angst J et al. (2002) World Federation of Societies of Biol Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatr 3: 5-43
14. Bauer M, Whybrow PC, Angst J et al. (2002) World Federation of Societies of Biol Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatr 3: 69-86
15. Baumann P, Nil R, Souche A et al. (1996) A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 16: 307-314
16. Browne M, Lapierre YD, Hrdina PD, Horn E (1990) Lithium as an adjunct in the treatment of major depression. Int Clin Psychopharmacol 5: 103-110
17. Bschor T (2005) Depression. In: Linden M, Müller WE (Hrsg) Rehabilitations-Psychopharmakotherapie. Deutscher Ärzte-Verlag, Köln, S 227-251
18. Bschor T, Adli M, Baethge C et al. (2002) Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 27: 470-478
19. Bschor T, Baethge C, Adli M et al. (2003) Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder. J Psychiat Res 37: 135-143
20. Bschor T, Baethge C, Adli M et al. (2003) Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depress Anxiety 17: 43-48
21. Bschor T, Bauer M (2004) Is successful lithium augmentation limited to serotonergic antidepressants? [Brief]. J Clin Psychopharmacol 24: 240-241
22. Bschor T, Bauer M (2004) Therapieresistente Depressionen. In: Lemke RM (Hrsg) Affektive Störungen. Thieme Verlag, Stuttgart, S 101-115
23. Bschor T, Bauer M (2006) Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 12: 2985-2992
24. Bschor T, Berghöfer A, Ströhle A et al. (2002) How long should the lithium augmentation strategy be maintained? A 1-year follow up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 22: 427-430
25. Bschor T, Canata B, Müller-Oerlinghausen B, Bauer M (2001) Predictors of response to lithium augmentation in tricyclic antidepressant- resistant depression. J Affect Disord 64: 261-265
26. Bschor T, Lewitzka U, Bauer M (2003) Lithiumaugmentation zur Behandlung der bipolaren Depression. Psychoneuro 29: 392-399
27. Burgess S, Geddes J, Hawton K et al. (eds) (2002) Lithium for maintenance treatment of mood disorders (Cochrane Review). In: The Cochrane Library, Issue 3, Oxford, Update Software
28. Cade JFJ (1949) Lithium salts in the treatment of psychotic-excitement. Med J Aust 36: 349-352
29. Chaput Y, De Montigny C, Blier P (1991) Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5: 219-229
30. Christodoulou GN, Lykouras EP (1982) Abrupt lithium discontinuation in manic- depressive patients. Acta Psychiatr Scand 65: 310-314
31. Cowen PJ, McCance SL, Ware CJ et al. (1991) Lithium in tricyclic-resistant depression. Correlation of increased brain 5-HT function with clinical outcome. Br J Psychiatry 159: 341-346
32. De Montigny C (1991) Lithium addition in treatment-resistant depression: evidence for the involvement of the serotonin system. In: Racagni G, Brunello N, Fukuda T (eds) Biol Psychiatry. Volume 1. Elsevier Science Publishers B.V., Amsterdam, pp 243-244
33. De Montigny C, Aghajanian GK (1978) Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202: 1303-1306
34. De Montigny C, Cournoyer G, Morisette R (1983) Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antideoressant drugs and lithium on the serotonin system. Arch Gen Psychiatry 40: 1327-1334
35. De Montigny C, Elie R, Caille G (1985) Rapid response to the addition of lithium in iprindole-resistant unipolar depression: a pilot study. Am J Psychiatry 142: 220-223
36. De Montigny C, Grunberg F, Mayer A, Deschenes JP (1981) Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 138: 252-256
37. Delgado PL, Price LH, Charney DS Heninger GR (1988) Efficacy of fluvoxamine in treatment refractory depression. J Affect Disord 15: 55-60
38. Dinan TG (1993) Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Acta Psychiatr Scand 88: 300-301
39. Dinan TG, Barry S (1989) A comparison of electroconvulsive therapy with a combined lithium and tricyclic combination among depressed tricyclic nonresponders. Acta Psychiatr Scand 80: 97-100
40. Fava M, Alpert J, Nierenberg A et al. (2002) Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 22: 379-387
41. Fava M, Rosenbaum JF, McGrath PJ et al. (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 151: 1372-1374
42. Felber W (1987) Die Lithiumprophylaxe der Depression vor 100 Jahren - ein genialer Irrtum. Fortschr Neurol Psychiatr 55: 141-144
43. Flint AJ, Rifat SL (1994) A prospective study of lithium augmentation in antidepressant-resistant geriatric depression. J Clin Psychopharmacol 14: 353-356
44. Fontaine R, Ontiverod A, Elie R, Vézina M (1991) Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression. Biol Psychiatry 29: 946-948
45. Hawley CJ, Roberts AG, Baldwin DS (1994) Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions. Int Clin Psychopharmacol 9: 31-33
46. Hawley CJ, Roberts AG, Walker MH (1994) Tolerability of combined treatment with lithium and paroxetine: 19 cases treated under open conditions. Int Clin Psychopharmacol 8: 266-267
47. Heninger GR, Charney DS, Sternberg DE (1983) Lithium carbonate augmentation of antidepressant treatment. Arch Gen Psychiatry 40: 1335-1342
48. Heuser IJE, Schweiger U, Gotthardt U et al. (1996) Pituitary-adrenal- system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 153: 93-99
49. Hoencamp E, Haffmans PMJ, Dijken WA (1994) Brofaromine versus lithium addition to maprotiline: a double blind study in maprotiline refractory depressed outpatients. J Affect Disord 30: 219-227
50. Hoencamp E, Haffmans PMJ, Dijken WA, Huijbrechts I (2000) Lithium augmentation of venlafaxine: an open-label trial. J Clin Psychiatry 20: 538-543
51. Holsboer-Trachsler E, Hemmeter U, Hatzinger M et al. (1994) Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment-neurobiological and psychometric assessment of course. J Psychiatr Res 28: 381-399
52. Joffe RT, Levitt AJ, Bagby RM et al. (1993) Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 163: 574-578
53. Joffe RT, Singer W, Levitt AJ, MacDonald C (1993) A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 50: 387-393
54. Juckel G, Mavrogiorgou P (2006) Interaction of lithium with neurotransmitter systems: serotonin and others. In: Bauer M, Grof P, Müller-Oerlinghausen B (eds) Lithium in neuropsychiatry. The comprehensive guide. Informa healthcare, London, pp 329-340
55. Kantor D, McNevin S, Leichner P et al. (1986) The benefit of lithium carbonate adjunct in refractory depression - fact or fiction? Can J Psychiatry 31: 416-418
56. Katona CLE, Abou-Saleh MT, Harrison DA et al. (1995) Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 166: 80-86
57. Lange C (ed) (1886) Om periodiske Depressionstilstande og deres Patogenese. Jacob Lunds Forlag, Kopenhagen
58. Linden M, Helmchen H, Mackert A, Müller-Oerlinghausen B (1994) Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed inpatients. Pharmacopsychiatry 27 [Suppl]: 51-53
59. McCance-Katz E, Price LH, Charney DS, Heninger GR (1992) Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology 108: 93-97
60. Nelson JC (1998) Overcoming treatment resistance in depression. J Clin Psychiatry [Suppl 16] 59: 13-19
61. Nemeroff CB (1996) Augmentation strategies in patients with refractory depression. Depress Anxiety 4: 169-181
62. Nierenberg AA, Papakostas GI, Petersen T et al. (2003) Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 23: 92-95
63. Platman SR, Fieve RR (1968) Lithium carbonate and plasma cortisol response in the affective disorders. Arch Gen Psychiatry 18: 591-594
64. Platman SR, Hilton JG, Koss MC, Kelly WG (1971) Production of cortisol in patients with manic-depressive psychosis treated with lithium carbonate. Dis Nerv Syst 32: 542-544
65. Price LH, Carpenter LL, Rasmussen SA (2001) Drug combination strategies. In: Amsterdam JD, Hornig M, Nierenberg AA (eds) Treatment-resistant mood disorders. Univ Press, Cambridge, pp 194-222
66. Price LH, Charney DS, Delgado PL et al. (1990) Clinical studies of 5-HT function using i.v. L-tryptophan. Prog Neuropsychopharmacol Biol Psychiatry 14: 459-472
67. Price LH, Charney DS, Henninger GR (1986) Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 143: 1387-1392
68. Reisine T, Zatz M (1987) Interactions among lithium, calcium, diacylglycerides, and phorbolesters in the regulation of adrenocorticotropin hormone release from AtT-20 cells. J Neurochem 49: 884-889
69. Rybakowski J, Matkowski K (1992) Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. Eur Neuropsychopharmacol 2: 161-165
70. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. J Neuropsychiatry Clin Neurosci 7: 524-533
71. Schöpf J, Baumann P, Lemarchand T, Rey M (1989) Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiatry 22: 183-187
72. Sluzeska A, Sobieska M, Rybakowski JK (1997) Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Biol Psychiatry 35: 123-127
73. Souza FG, Goodwin GM (1991) Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 158: 666-675
74. Stein G, Bernadt M (1993) Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 162: 634-640
75. Sugawara M, Hashimoto K, Hattori T et al. (1988) Effects of lithium on the hypothalamo-pituitary-adrenal axis. Endocrinol Jpn 35: 655-663
76. Uehlinger C, Nil R, Amey M et al. (1995) Citalopram-lithium combination treatment of elderly depressed patients: a pilot study. Int J Ger Psychiatry 10: 281-287
77. Zatz M, Reisine TD (1985) Lithium induces corticotropin secretion and desensitization in cultured anterior pituitary cells. Proc Natl Acad Sci U S A 82: 1286-1290
78. Zusky PM, Biederman J, Rosenbaum JF et al. (1988) Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 8: 120-124